-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KfH4i3btSZ3lCNcHcE2z/mat+bbJOKBHa+rflyLk/i/vJ9oqUK/iDHhgiiwfwX2z LYbvL0jgNe8IUn+WjBj41g== 0000919015-02-000008.txt : 20020813 0000919015-02-000008.hdr.sgml : 20020813 20020813115038 ACCESSION NUMBER: 0000919015-02-000008 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20020813 ITEM INFORMATION: Other events FILED AS OF DATE: 20020813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPHERE MEDICAL INC CENTRAL INDEX KEY: 0000919015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043216867 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23678 FILM NUMBER: 02728471 BUSINESS ADDRESS: STREET 1: 1050 HINGHAM STREET CITY: ROCKLAND STATE: MA ZIP: 02370 BUSINESS PHONE: 7816817900 MAIL ADDRESS: STREET 1: 1050 HINGHAM STREET CITY: ROCKLAND STATE: MA ZIP: 02370 FORMER COMPANY: FORMER CONFORMED NAME: BIOSEPRA INC DATE OF NAME CHANGE: 19940215 8-K 1 body.txt NEW CEO PRESS RELEASE 1 ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 -------------- FORM 8-K CURRENT REPORT -------------- PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 -------------------------------------- Date of Report (Date of earliest event reported): August 13, 2002 BIOSPHERE MEDICAL, INC. -------------------------------------------------------------- (Exact name of registrant as specified in its Charter) Delaware 0-23678 04-3216867 ------------------------- ------------ ----------------- (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.) 1050 Hingham St. Rockland, Massachusetts 02370 ---------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (781) 681-7900 ---------------------------------------------------- (Former Name or Former Address if Changed Since Last Report) ================================================================================ 2 ITEM 5. OTHER EVENTS On August 13, 2002, BioSphere Medical, Inc. issued a press release (which is attached hereto as Exhibit 99.1) announcing the election of Paul A. Looney as President and Chief Executive Officer. ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS (c) Exhibits. Exhibit 99.1 The Registrant's Press Release dated August 13, 2002. 3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOSPHERE MEDICAL, INC. (Registrant) Date: August 13, 2002 By: /s/ Robert M. Palladino ________________________________ Vice President and Chief Financial Officer 4 EXHIBIT INDEX Exhibit Number Description ______ ______________________________ 99.1 The Registrant's Press Release dated August 13, 2002 EX-99.1 3 pressrelease.txt REGISTRANTS PRESS RELEASE Exhibit 99.1 [Company Logo] Contact: Robert M. Palladino 781-681-7925 BIOSPHERE MEDICAL(TM)ELECTS PAUL A. LOONEY AS PRESIDENT AND CHIEF EXECUTIVE OFFICER Paul A. Looney to assume new leadership role in addition to Chairman of the Board ROCKLAND, MA, August 13, 2002 - BioSphere Medical, Inc. (Nasdaq: BSMD) today announced that Paul A. Looney has been elected as its President and Chief Executive Officer effective immediately. Mr. Looney will continue to serve as Chairman of BioSphere Medical's Board of Directors. Mr. Looney has served as a director of BioSphere Medical since 1994. Prior to his election as President and Chief Executive Officer of BioSphere Medical, Mr. Looney was most recently the President and Chief Operating Officer of Biopure Corporation. Prior to that position, he served as President and Chief Executive Officer of Corning Costar Corporation and Chief Operating Officer of Millipore Corporation. "As a long-time supporter of BioSphere Medical, I am very excited about being more involved in the day-to-day operations", stated Mr. Looney. "We are defining opportunities that we believe will maximize our leadership in embolotherapy and interventional radiology." About BioSphere Medical, Inc. BioSphere Medical, Inc. (the "Company"), based in Rockland, Massachusetts, is a medical device company focused on embolotherapy, the treatment of tumors and vascular malformations by occluding their blood supply. The Company is pioneering the use of patented and proprietary bioengineered microspheres as a new class of embolics. BioSphere Medical's lead products, Embosphere(R) Microspheres and EmboGold(TM) Microspheres, have been cleared by the FDA for marketing for hypervascularized tumors and vascular malformations. The Company has filed a 510(k) application and is currently awaiting a decision by FDA on expanded labeling that would include use of Embosphere(R) Microspheres for uterine fibroid embolization (UFE) in the United States. BioSphere Medical has received CE Mark approval in the European Community and approvals in Canada and Australia which allow the Company to sell Embosphere(R) Microspheres and EmboGold(TM) Microspheres for use in general embolization procedures, including uterine fibroid embolization. For additional information about BioSphere Medical, see the Company's website at www.biospheremed.com. Statements in this press release that are not strictly historical are forward-looking statements. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the Company's operations and business environment. These risks include, without limitation, the Company's stage of product development, history of operating losses and accumulated deficits, uncertainties and possible delays related to the filing and acceptance of applications to the FDA and foreign regulatory authorities, the uncertainties of clinical trials, possible healthcare reform, manufacturing capacity, marketing, market acceptance, competition and the availability of sufficient financing to support operations. Discussions of BioSphere Medical's operations and financial condition, and specific factors that could cause the Company's actual performance to differ from current expectations, can be found in the Company's filings with the U.S. Securities and Exchange Commission, which can be accessed in the EDGAR database at the SEC Web site, http://www.sec.gov. -----END PRIVACY-ENHANCED MESSAGE-----